<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002030</url>
  </required_header>
  <id_info>
    <org_study_id>022E</org_study_id>
    <secondary_id>87-72B</secondary_id>
    <secondary_id>88-21</secondary_id>
    <nct_id>NCT00002030</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients</brief_title>
  <official_title>An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisons</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and efficacy of long term, bi-weekly administration of&#xD;
      aerosol pentamidine when used as a prophylactic agent in patients who have had at least two&#xD;
      or more episodes of AIDS-associated Pneumocystis carinii pneumonia (PCP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine isethionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Standard or experimental treatments for an opportunistic infection or neoplasm&#xD;
             (including aerosolized or intravenous pentamidine) that develops during the study.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Any standard or experimental treatment for an opportunistic infection or neoplasm that&#xD;
             develops during the study.&#xD;
&#xD;
        Patients must have AIDS with at least one cytologically or histologically proven episode of&#xD;
        Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Patients must be free of acute medical problems.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Requiring ongoing active therapy for an opportunistic infection at the time of study&#xD;
             entry.&#xD;
&#xD;
          -  Toxoplasmosis.&#xD;
&#xD;
          -  Cryptococcus.&#xD;
&#xD;
          -  Pulmonary Kaposi's sarcoma (KS).&#xD;
&#xD;
          -  Asthma poorly controlled by medication.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Pentamidine by any route other than aerosolized or intravenous or any other&#xD;
             experimental agent for chemoprophylaxis of PCP while on the study (e.g.:&#xD;
&#xD;
          -  Septra, Fansidar, Dapsone, or eflornithine).&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Transfusion dependency defined as &gt; 1 blood transfusion per month.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at the time of&#xD;
             entry or having either Toxoplasmosis or cryptococcosis at entry.&#xD;
&#xD;
          -  Pulmonary Kaposi's sarcoma (KS).&#xD;
&#xD;
          -  Active substance abuse by patients who cannot comply with study procedures.&#xD;
&#xD;
          -  Unwilling to sign informed consent.&#xD;
&#xD;
          -  In the opinion of the investigator cannot cooperate with study procedure.&#xD;
&#xD;
          -  Asthma poorly controlled by medication.&#xD;
&#xD;
          -  Patients may not receive pentamidine by any other route than aerosolized or&#xD;
             intravenous or any other experimental agent for chemoprophylaxis of PCP while on the&#xD;
             study (e.g.:&#xD;
&#xD;
          -  Septra, Fansidar, Dapsone, or eflornithine).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Antiretroviral agents, excluding zidovudine (AZT).&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 7 days of study entry:&#xD;
&#xD;
          -  Blood transfusion.&#xD;
&#xD;
          -  Excluded:&#xD;
&#xD;
          -  Requiring ongoing active treatments for an opportunistic infection at time of study&#xD;
             entry.&#xD;
&#xD;
        Active substance abuse by patients who cannot comply with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fisons Corp</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Pentamidine</keyword>
  <keyword>Aerosols</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

